Rituximab
Rituxan / MabThera · Anti-CD20 antibody · CD20
Chimeric monoclonal antibody targeting CD20 on B cells. Backbone of all MCL immunochemotherapy regimens and maintenance therapy.
Backbone of frontline and maintenance therapy in MCL
Hanneke Kluin-Nelemans
Professor Emerita of Hematology · University Medical Center Groningen
Martin Dreyling
Professor of Medicine · Department of Medicine III, LMU University Hospital
Mats Jerkeman
Professor of Clinical Oncology · Lund University / Skane University Hospital
Steven Le Gouill
Director of Hospital Group and Professor of Hematology · Institut Curie / Paris-Saclay University
Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario.
Blood neoplasia · May 2026
Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18 F-FDG PET/CT.
Clinical nuclear medicine · May 2026
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.
Nature communications · Mar 2026
Epidemiology, treatment patterns, and survival outcomes of patients with mantle cell lymphoma in Germany: a retrospective analysis of administrative claims data.
Annals of hematology · Mar 2026
Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.
Leukemia & lymphoma · Mar 2026
CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: An Unusual Presentation.
The American Journal of dermatopathology · Mar 2026
Diffuse Gastrointestinal Polyposis Revealing Mantle Cell Lymphoma: A Case Highlighting a Diagnostic Pitfall.
Cureus · Mar 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 2026
IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.
Blood advances · Feb 2026
[Acalabrutinib plus bendamustine and rituximab for older patients with untreated mantle cell lymphoma].
Bulletin du cancer · Feb 2026
Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy.
Future oncology (London, England) · Feb 2026
[Clinical Analysis of Autologous Hematopoietic Stem Cell Transplantation in Treatment of Mantle Cell Lymphoma: a Multicenter Retrospective Study].
Zhongguo shi yan xue ye xue za zhi · Feb 2026
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
Blood advances · Jan 2026
Mantle Cell Lymphoma Mimicking Parotid Neoplasm: A Rare Case Report.
Iranian journal of otorhinolaryngology · Jan 2026
Lineage-determining transcription factors constrain cohesin to drive multi-enhancer oncogene regulation.
Nature cell biology · Jan 2026
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
Leukemia · Jan 2026
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
European journal of haematology · Dec 2025
Chronic meningoencephalitis due to enterovirus A71 complicating rituximab therapy.
Revue neurologique · Dec 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.
Nature communications · Nov 2025